SG Americas Securities LLC Has $564,000 Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)

SG Americas Securities LLC cut its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 62.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,187 shares of the biotechnology company's stock after selling 18,476 shares during the period. SG Americas Securities LLC's holdings in Corcept Therapeutics were worth $564,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of CORT. Capital Performance Advisors LLP bought a new position in Corcept Therapeutics in the third quarter valued at about $25,000. Kathleen S. Wright Associates Inc. bought a new position in shares of Corcept Therapeutics in the 3rd quarter valued at about $36,000. USA Financial Formulas acquired a new position in Corcept Therapeutics in the fourth quarter valued at approximately $54,000. GAMMA Investing LLC boosted its stake in Corcept Therapeutics by 85.4% in the third quarter. GAMMA Investing LLC now owns 2,490 shares of the biotechnology company's stock valued at $115,000 after acquiring an additional 1,147 shares during the last quarter. Finally, KBC Group NV grew its holdings in Corcept Therapeutics by 21.3% during the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 496 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.88, for a total value of $131,736.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Joseph Douglas Lyon sold 1,411 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $56.72, for a total value of $80,031.92. Following the transaction, the insider now owns 8,494 shares of the company's stock, valued at approximately $481,779.68. This trade represents a 14.25 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 28,011 shares of company stock worth $1,461,568. 20.50% of the stock is owned by company insiders.

Corcept Therapeutics Trading Up 0.5 %

NASDAQ:CORT traded up $0.36 on Tuesday, reaching $66.91. The company's stock had a trading volume of 776,122 shares, compared to its average volume of 898,733. Corcept Therapeutics Incorporated has a 1-year low of $20.84 and a 1-year high of $71.29. The business's 50-day moving average price is $56.34 and its two-hundred day moving average price is $47.56. The firm has a market cap of $7.01 billion, a PE ratio of 53.10 and a beta of 0.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. StockNews.com downgraded Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 25th. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a "buy" rating in a report on Thursday, January 30th. Sandler O'Neill restated a "buy" rating on shares of Corcept Therapeutics in a research report on Friday, October 18th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $88.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.